Ceftriaxone (gastrointestinal lumen) (CRO)

Ceftriaxone in the gastrointestinal lumen refers to the fraction of the parenterally administered antibiotic that is excreted via the bile into the small intestine. While ceftriaxone is intended to treat systemic infections by inhibiting bacterial cell wall synthesis, its presence in the gut is a major driver of collateral damage to the commensal microbiome (StatPearls, 2023). This biliary excretion leads to high concentrations of the active drug in the intestinal tract, which eliminates beneficial bacteria and facilitates the overgrowth of opportunistic pathogens like Clostridioides difficile (Kokai-Kun et al., 2017). Consequently, this localized pool of antibiotic has become a therapeutic target for drugs designed to protect the microbiome. Agents such as ribaxamase (an oral beta-lactamase) and DAV132 (a targeted adsorbent) act specifically within the GI lumen to degrade or sequester ceftriaxone before it reaches the colon (de Gunzburg et al., 2018). By targeting ceftriaxone in this specific compartment, these therapies aim to prevent antibiotic-associated diarrhea and the development of antimicrobial resistance without compromising the drug's primary therapeutic effect in the bloodstream. This approach represents a novel paradigm in infectious disease management where the drug itself, rather than a host protein, serves as the target for intervention.

Other names

Biliary ceftriaxoneFecal ceftriaxoneResidual intestinal ceftriaxoneIntraluminal ceftriaxone

Enzymatic hydrolysis of the beta-lactam ring or physical adsorption and sequestration within the gastrointestinal tract